Toltrazuril treatment to control diaplacental Neospora caninum transmission in experimentally infected pregnant mice.
We addressed the question whether diaplacental transmission of Neospora caninum can be controlled by metaphylactic chemotherapy using toltrazuril or enrofloxacin. Female C57/BL6 mice, infected on day 10 of pregnancy, were medicated for 6 consecutive days p.i. with 52.5 mg toltrazuril or - as an out-group control medication--16.7 mg enrofloxacin per kg body weight per day. Other control groups received either infection but no medication or vice versa. Toltrazuril treatment significantly reduced pre- and perinatal losses (10 deliveries of healthy newborns, versus 1 abortion and 4 failures) when compared to control-enrofloxacin (2 deliveries, versus 1 abortion, 7 failures and 2 pre-parturient deaths of dams) and non-treated animals (3 deliveries, versus 6 abortions, 8 failures and 4 pre-parturient deaths). Simultaneously, PCR-based parasite detection in the brain of mothers, histopathological findings as well as clinical fatality were significantly less frequent in toltrazuril-treated dams. The overall toltrazuril treatment efficacy was determined as 87 %, that of enrofloxacin-treatment as 17 %. The progenies of toltrazuril-treated dams also exhibited a very low rate of PCR-positivity in their brain (3 out of 39), whereas untreated dams delivered litters with mostly PCR-positive brains (12 out of 14) and a relatively high death rate post-partum (5 out of 19 newborns died). Mice subjected to a second mating delivered newborns all negative by N. caninum-PCR, indicating that diaplacental tachyzoite passage does not occur in a later, repeated pregnancy. Overall, our experiments showed that toltrazuril-treatment of an acute N. caninum-infection--induced during pregnancy--results in a clear reduction of fetal losses and a marked reduction of diaplacental passage of the parasite to the fetal brain, whereas enrofloxacin, as an out-group control substance, failed to show the same effect.
Gottstein
B
B
Institute of Parasitology, University of Berne, Länggass-Strasse 122, CH-3012 Berne, Switzerland. bruno.gottstein@ipa.unibe.ch
Razmi
G R
GR
Ammann
P
P
Sager
H
H
Müller
N
N
D000818:Animals; D000831:Animals, Newborn / Q000469:parasitology; D001921:Brain / Q000469:parasitology; D003048:Coccidiosis / Q000188:drug therapy* / Q000635:transmission / Q000662:veterinary; D003049:Coccidiostats / Q000627:therapeutic use*; D016054:DNA, Protozoan / Q000378:metabolism; D000077422:Enrofloxacin; D005260:Female; D024841:Fluoroquinolones / Q000627:therapeutic use; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control* / Q000662:veterinary; D051379:Mice; D008810:Mice, Inbred C57BL; D018688:Neospora / Q000187:drug effects* / Q000302:isolation & purification; D011247:Pregnancy; D015363:Quinolones / Q000627:therapeutic use; D014227:Triazines / Q000627:therapeutic use*
D003049:Coccidiostats; D016054:DNA, Protozoan; D024841:Fluoroquinolones; D015363:Quinolones; D014227:Triazines; D000077422:Enrofloxacin; C036670:toltrazuril